Suh J K,Kang S, Kim H, et al. Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell Histiocytosis[J]. Blood Res, 2021, 56(S1):S65-S69.
Morimoto A,Shioda Y,I Mamura T,et al.Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions:Results of the Japan Langerhans cell histiocytosis study group-02 protocol study[J].International Jour of Hemat,2018,108(2):192-198.
Lee H J,AhnB C,Lee S W,et al.Theusefulness of F-18 fluorodeoxyglucose positron emission tomgraphy/computed tomography in patients with Langerhans cell histiocytosis[J].Ann Nucl Med,2012,26(9):730-737.
Keerberghen C A,Harrouk A,Leone L.A new role for fluorine 18-fluorodeoxyglucose positron-emission tomography/computed tomography in Erdheim-Chester disease[J].World journal of nuclear medicine,2019,18: 201-203.
[24]
Malik D, Kumar R,Mittal BR,et al. Langerhans Cell histiocytosis masquerading as metastatic papillary thyroid cancer on 18F-FDG PET /CT: diagnostic dilemma solved by PET /CT-guided biopsy[J].Nucl Med Mol Imaging,2018,52: 394-397.
[25]
Obert J,Vercellino L,Gucht A,et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis[J].Eur J Nucl Med Mol Imaging,2017,44: 598-610.